Sumoylation pathway is required to maintain the basal breast cancer subtype

Cancer Cell

Volumn 25, Issue 6, 2014, Pages 748-761

  Bogachek, Maria V ^a   Chen, Yizhen ^a   Kulak, Mikhail V ^a   Woodfield, George W ^a   Cyr, Anthony R ^a   Park, Jung M ^a   Spanheimer, Philip M ^a   Li, Yingyue ^a   Li, Tiandao ^a,b   Weigel, Ronald J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LYSINE; SUMO PROTEIN; TRANSCRIPTION FACTOR AP 2; TRANSCRIPTION FACTOR TFAP2A; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; MUTATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; STRUCTURE ACTIVITY RELATION; SUMOYLATION; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICE; MICE, NUDE; MULTIGENE FAMILY; NEOPLASMS, BASAL CELL; SMALL UBIQUITIN-RELATED MODIFIER PROTEINS; SUMOYLATION; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902533387     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2014.04.008     Document Type: Article

References (72)

1. Abdel-Hafiz H.A., Horwitz K.B. Control of progesterone receptor transcriptional synergy by SUMOylation and deSUMOylation. BMC Mol. Biol. 2012, 13:10.
2. Ailan H., Xiangwen X., Daolong R., Lu G., Xiaofeng D., Xi Q., Xingwang H., Rushi L., Jian Z., Shuanglin X. Identification of target genes of transcription factor activator protein 2 gamma in breast cancer cells. BMC Cancer 2009, 9:279.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. USA 2003, 100:3983-3988.
4. Allouche A., Nolens G., Tancredi A., Delacroix L., Mardaga J., Fridman V., Winkler R., Boniver J., Delvenne P., Begon D.Y. The combined immunodetection of AP-2alpha and YY1 transcription factors is associated with ERBB2 gene overexpression in primary breast tumors. Breast Cancer Res. 2008, 10:R9.
5. Bai F., Smith M.D., Chan H.L., Pei X.H. Germline mutation of Brca1 alters the fate of mammary luminal cells and causes luminal-to-basal mammary tumor transformation. Oncogene 2013, 32:2715-2725.
6. Balko J.M., Miller T.W., Morrison M.M., Hutchinson K., Young C., Rinehart C., Sánchez V., Jee D., Polyak K., Prat A., et al. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium. Proc. Natl. Acad. Sci. USA 2012, 109:221-226.
7. Begon D.Y., Delacroix L., Vernimmen D., Jackers P., Winkler R. Yin Yang 1 cooperates with activator protein 2 to stimulate ERBB2 gene expression in mammary cancer cells. J.Biol. Chem. 2005, 280:24428-24434.
8. Berlato C., Chan K.V., Price A.M., Canosa M., Scibetta A.G., Hurst H.C. Alternative TFAP2A isoforms have distinct activities in breast cancer. Breast Cancer Res. 2011, 13:R23.
9. Bernardo G.M., Bebek G., Ginther C.L., Sizemore S.T., Lozada K.L., Miedler J.D., Anderson L.A., Godwin A.K., Abdul-Karim F.W., Slamon D.J., Keri R.A. FOXA1 represses the molecular phenotype of basal breast cancer cells. Oncogene 2013, 32:554-563.
10. Bertucci F., Finetti P., Birnbaum D. Basal breast cancer: a complex and deadly molecular subtype. Curr. Mol. Med. 2012, 12:96-110.
11. Bettermann K., Benesch M., Weis S., Haybaeck J. SUMOylation in carcinogenesis. Cancer Lett. 2012, 316:113-125.
12. Bosher J.M., Totty N.F., Hsuan J.J., Williams T., Hurst H.C. A family of AP-2 proteins regulates c-erbB-2 expression in mammary carcinoma. Oncogene 1996, 13:1701-1707.
13. Bossis G., Melchior F. Regulation of SUMOylation by reversible oxidation of SUMO conjugating enzymes. Mol. Cell 2006, 21:349-357.
14. Buchwalter G., Hickey M.M., Cromer A., Selfors L.M., Gunawardane R.N., Frishman J., Jeselsohn R., Lim E., Chi D., Fu X., et al. PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells. Cancer Cell 2013, 23:753-767.
15. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., Karaca G., Troester M.A., Tse C.K., Edmiston S., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
16. Carr J.R., Kiefer M.M., Park H.J., Li J., Wang Z., Fontanarosa J., DeWaal D., Kopanja D., Benevolenskaya E.V., Guzman G., Raychaudhuri P. FoxM1 regulates mammary luminal cell fate. Cell Rep. 2012, 1:715-729.
17. Chakrabarti R., Wei Y., Romano R.A., DeCoste C., Kang Y., Sinha S. Elf5 regulates mammary gland stem/progenitor cell fate by influencing notch signaling. Stem Cells 2012, 30:1496-1508.
18. Chen C.H., Chang C.C., Lee T.H., Luo M., Huang P., Liao P.H., Wei S., Li F.A., Chen R.H., Zhou X.Z., et al. SENP1 deSUMOylates and regulates Pin1 protein activity and cellular function. Cancer Res. 2013, 73:3951-3962.
19. Chu Y., Yang X. SUMO E3 ligase activity of TRIM proteins. Oncogene 2011, 30:1108-1116.
20. Cubeñas-Potts C., Matunis M.J. SUMO: a multifaceted modifier of chromatin structure and function. Dev. Cell 2013, 24:1-12.
21. Cyr A.R., Kulak M.V., Park J.M., Bogachek M.V., Spanheimer P.M., Woodfield G.W., White-Baer L.S., O'Malley Y.Q., Sugg S.L., Olivier A.K., et al. TFAP2C governs the luminal epithelial phenotype in mammary development and carcinogenesis. Oncogene 2014, Published online January 27, 2014. 10.1038/onc.2013.569.
22. deConinck E.C., McPherson L.A., Weigel R.J. Transcriptional regulation of estrogen receptor in breast carcinomas. Mol. Cell. Biol. 1995, 15:2191-2196.
23. Delacroix L., Begon D., Chatel G., Jackers P., Winkler R. Distal ERBB2 promoter fragment displays specific transcriptional and nuclear binding activities in ERBB2 overexpressing breast cancer cells. DNA Cell Biol. 2005, 24:582-594.
24. Eckert D., Buhl S., Weber S., Jäger R., Schorle H. The AP-2 family of transcription factors. Genome Biol. 2005, 6:246.
25. Eloranta J.J., Hurst H.C. Transcription factor AP-2 interacts with the SUMO-conjugating enzyme UBC9 and is sumolated invivo. J.Biol. Chem. 2002, 277:30798-30804.
26. Fang S.H., Chen Y., Weigel R.J. GATA-3 as a marker of hormone response in breast cancer. J.Surg. Res. 2009, 157:290-295.
27. Feng W., Williams T. Cloning and characterization of the mouse AP-2 epsilon gene: a novel family member expressed in the developing olfactory bulb. Mol. Cell. Neurosci. 2003, 24:460-475.
28. Feng Z.J., Gurung B., Jin G.H., Yang X.L., Hua X.X. SUMO modification of menin. Am. J. Cancer Res. 2013, 3:96-106.
29. Friedrichs N., Jäger R., Paggen E., Rudlowski C., Merkelbach-Bruse S., Schorle H., Buettner R. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod. Pathol. 2005, 18:431-438.
30. Friedrichs N., Steiner S., Buettner R., Knoepfle G. Immunohistochemical expression patterns of AP2alpha and AP2gamma in the developing fetal human breast. Histopathology 2007, 51:814-823.
31. Fukuda I., Ito A., Hirai G., Nishimura S., Kawasaki H., Saitoh H., Kimura K., Sodeoka M., Yoshida M. Ginkgolic acid inhibits protein SUMOylation by blocking formation of the E1-SUMO intermediate. Chem. Biol. 2009, 16:133-140.
32. Gill G. Post-translational modification by the small ubiquitin-related modifier SUMO has big effects on transcription factor activity. Curr. Opin. Genet. Dev. 2003, 13:108-113.
33. Girdwood D., Bumpass D., Vaughan O.A., Thain A., Anderson L.A., Snowden A.W., Garcia-Wilson E., Perkins N.D., Hay R.T. P300 transcriptional repression is mediated by SUMO modification. Mol. Cell 2003, 11:1043-1054.
34. Herschkowitz J.I., Simin K., Weigman V.J., Mikaelian I., Usary J., Hu Z., Rasmussen K.E., Jones L.P., Assefnia S., Chandrasekharan S., et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007, 8:R76.
35. Hoffman T.L., Javier A.L., Campeau S.A., Knight R.D., Schilling T.F. Tfap2 transcription factors in zebrafish neural crest development and ectodermal evolution. J.Exp. Zoolog. B Mol. Dev. Evol. 2007, 308:679-691.
36. Holmstrom S.R., Chupreta S., So A.Y., Iñiguez-Lluhí J.A. SUMO-mediated inhibition of glucocorticoid receptor synergistic activity depends on stable assembly at the promoter but not on DAXX. Mol. Endocrinol. 2008, 22:2061-2075.
37. Ihara M., Stein P., Schultz R.M. UBE2I (UBC9), a SUMO-conjugating enzyme, localizes to nuclear speckles and stimulates transcription in mouse oocytes. Biol. Reprod. 2008, 79:906-913.
38. Iqbal J., Chong P.Y., Tan P.H. Breast cancer stem cells: an update. J.Clin. Pathol. 2013, 66:485-490.
39. Jäger R., Werling U., Rimpf S., Jacob A., Schorle H. Transcription factor AP-2gamma stimulates proliferation and apoptosis and impairs differentiation in a transgenic model. Mol. Cancer Res. 2003, 1:921-929.
40. Johnson E.S., Blobel G. Ubc9p is the conjugating enzyme for the ubiquitin-like protein Smt3p. J.Biol. Chem. 1997, 272:26799-26802.
41. Joshi H., Nord S.H., Frigessi A., Børresen-Dale A.L., Kristensen V.N. Overrepresentation of transcription factor families in the genesets underlying breast cancer subtypes. BMC Genomics 2012, 13:199.
42. Jozwik K.M., Carroll J.S. Pioneer factors in hormone-dependent cancers. Nat. Rev. Cancer 2012, 12:381-385.
43. Kao J., Salari K., Bocanegra M., Choi Y.L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 2009, 4:e6146.
44. Kulak M.V., Cyr A.R., Woodfield G.W., Bogachek M., Spanheimer P.M., Li T., Price D.H., Domann F.E., Weigel R.J. Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer. Oncogene 2013, 32:4043-4051.
45. Lee H.E., Kim J.H., Kim Y.J., Choi S.Y., Kim S.W., Kang E., Chung I.Y., Kim I.A., Kim E.J., Choi Y., et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br. J. Cancer 2011, 104:1730-1738.
46. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., Pietenpol J.A. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J.Clin. Invest. 2011, 121:2750-2767.
47. Leitao B.B., Jones M.C., Brosens J.J. The SUMO E3-ligase PIAS1 couples reactive oxygen species-dependent JNK activation to oxidative cell death. FASEB J. 2011, 25:3416-3425.
48. Li W., Cornell R.A. Redundant activities of Tfap2a and Tfap2c are required for neural crest induction and development of other non-neural ectoderm derivatives in zebrafish embryos. Dev. Biol. 2007, 304:338-354.
49. McPherson L.A., Weigel R.J. AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs. Nucleic Acids Res. 1999, 27:4040-4049.
50. McPherson L.A., Baichwal V.R., Weigel R.J. Identification of ERF-1 as a member of the AP2 transcription factor family. Proc. Natl. Acad. Sci. USA 1997, 94:4342-4347.
51. McPherson L.A., Loktev A.V., Weigel R.J. Tumor suppressor activity of AP2alpha mediated through a direct interaction with p53. J.Biol. Chem. 2002, 277:45028-45033.
52. Moser M., Imhof A., Pscherer A., Bauer R., Amselgruber W., Sinowatz F., Hofstädter F., Schüle R., Buettner R. Cloning and characterization of a second AP-2 transcription factor: AP-2 beta. Development 1995, 121:2779-2788.
53. Orso F., Penna E., Cimino D., Astanina E., Maione F., Valdembri D., Giraudo E., Serini G., Sismondi P., De Bortoli M., Taverna D. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J. 2008, 22:2702-2714.
54. Pellikainen J., Naukkarinen A., Ropponen K., Rummukainen J., Kataja V., Kellokoski J., Eskelinen M., Kosma V.M. Expression of HER2 and its association with AP-2 in breast cancer. Eur. J. Cancer 2004, 40:1485-1495.
55. Ponti D., Costa A., Zaffaroni N., Pratesi G., Petrangolini G., Coradini D., Pilotti S., Pierotti M.A., Daidone M.G. Isolation and invitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005, 65:5506-5511.
56. Roederer M., Hardy R.R. Frequency difference gating: a multivariate method for identifying subsets that differ between samples. Cytometry 2001, 45:56-64.
57. Ryu J., Cho S., Park B.C., Lee H. Oxidative stress-enhanced SUMOylation and aggregation of ataxin-1: implication of JNK pathway. Biochem. Biophys. Res. Commun. 2010, 393:280-285.
58. Scibetta A.G., Wong P.P., Chan K.V., Canosa M., Hurst H.C. Dual association by TFAP2A during activation of the p21cip/CDKN1A promoter. Cell Cycle 2010, 9:4525-4532.
59. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
60. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA 2001, 98:10869-10874.
61. Tan S.K., Lin Z.H., Chang C.W., Varang V., Chng K.R., Pan Y.F., Yong E.L., Sung W.K., Cheung E. AP-2γ regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 2011, 30:2569-2581.
62. Torres J.Z., Miller J.J., Jackson P.K. High-throughput generationof tagged stable cell lines for proteomic analysis. Proteomics 2009, 9:2888-2891.
63. Turner B.C., Zhang J., Gumbs A.A., Maher M.G., Kaplan L., Carter D., Glazer P.M., Hurst H.C., Haffty B.G., Williams T. Expression of AP-2 transcription factors in human breast cancer correlates with the regulation of multiple growth factor signalling pathways. Cancer Res. 1998, 58:5466-5472.
64. Valentin M.D., da Silva S.D., Privat M., Alaoui-Jamali M., Bignon Y.J. Molecular insights on basal-like breast cancer. Breast Cancer Res. Treat. 2012, 134:21-30.
65. Williams T., Tjian R. Analysis of the DNA-binding and activationproperties of the human transcription factor AP-2. Genes Dev. 1991, 5:670-682.
66. Williams T., Tjian R. Characterization of a dimerization motif in AP-2 and its function in heterologous DNA-binding proteins. Science 1991, 251:1067-1071.
67. Williams T., Admon A., Lüscher B., Tjian R. Cloning and expression of AP-2, a cell-type-specific transcription factor that activates inducible enhancer elements. Genes Dev. 1988, 2(12A):1557-1569.
68. Woodfield G.W., Horan A.D., Chen Y., Weigel R.J. TFAP2C controls hormone response in breast cancer cells through multiple pathways of estrogen signaling. Cancer Res. 2007, 67:8439-8443.
69. Woodfield G.W., Chen Y., Bair T.B., Domann F.E., Weigel R.J. Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells. Genes Chromosomes Cancer 2010, 49:948-962.
70. Yang J.W., Lee E.Y., Kang K.W. ErbB2 overexpression in p53-inactivated mammary epithelial cells. FEBS Lett. 2006, 580:6501-6508.
71. Zhang J., Brewer S., Huang J., Williams T. Overexpression of transcription factor AP-2alpha suppresses mammary gland growth and morphogenesis. Dev. Biol. 2003, 256:127-145.
72. Zhao F., Satoda M., Licht J.D., Hayashizaki Y., Gelb B.D. Cloning and characterization of a novel mouse AP-2 transcription factor, AP-2delta, with unique DNA binding and transactivation properties. J.Biol. Chem. 2001, 276:40755-40760.